For patients with BRAF-mutant melanoma, four trials are exploring a combination of BRAF and MEK inhibitors agents, including BRAF inhibitor vemurafenib in combination with MEK inhibitor cobimetinib (NCT03430947 [66], NCT02537600 [67]), and BRAF inhibitor encorafenib combined with MEK inhibitor binimetinib (NCT03911869 [68], NCT04511013 [69], NCT03898908 [70]). This evidence concerns the gene MAP2K7 and melanoma.